Melanocyte-Stimulating Hormone and Parkinsonism

Shuster, Sam; Burton, J.L.; Thody, A. J.; Plummer, N. A.; Goolamali, S.K.; Bates, Duane

doi:10.1016/s0140-6736(73)92150-8

Cited by 13 publications

(16 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MC1 melanocortin receptor ( MC1R ) gene variants, reported to be associated with LMM,36 and possibly also with PD,4 especially did not account for the co-occurrence of PD and melanoma. 11 37 A possible mechanism linking LMM and PD may be polymorphisms in the MC3/MC4 melanocortin receptor ( MC3R , MC4R ) genes, which might alter the effect of the β-melanocyte-stimulating hormone 38 39. A number of other potential common mechanisms that deserve further exploration have been proposed earlier 4 5 8 9.…”

Section: Discussionmentioning

confidence: 99%

Frequency and profile of Parkinson's disease prodromi in patients with malignant melanoma

Walter

Heilmann

Voss

et al. 2015

J Neurol Neurosurg Psychiatry

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Frequency and profile of Parkinson's disease prodromi in patients with malignant melanoma

Walter

Heilmann

Voss

et al. 2015

J Neurol Neurosurg Psychiatry

View full text Add to dashboard Cite

show abstract

“…Later Shuster, Thody, Goolamali, Burton, Plummer and Bates (1973) demonstrated that plasma MSH values were elevated in Parkinson's disease. However this finding is still in doubt, mainly because the specificity of MSH determination is not as clear as previously thought.…”

Section: B-lph Derivatives and Parkinson's Diseasementioning

confidence: 99%

Peptides in Parkinson’s Disease

Barbeau

1978

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Pep tides have found a progressively more important role in the biochemistry ·and physiology of the brain in recent years. Hany possess neurological and behavioral actions in addition to their function in endocrinology. This paper reviews the formation and distribution, as well as the neurological action, of peptides probably involved in Parkinson's disease: 8-LPH and its derivatives (MSH, . It also recounts the experience of many authors with prolyl-leucyl-glycine-amide (PLG) in that disease. Finally we propose a new theory of the etiology of Parkinson's disease, based on a postulated deficiency in the important trophic function upon catecholaminergic neurons of A.P.U.D. cells. PEPTIDES IN THE BRAINThe last 15 years have seen the extraordinary growth of knowledge in the physiology, pharmacology and biochemistry of monoamines, particularly spurred on by the findings of abnormal dopamine metabolism in Parkinson's disease and the encouraging success of levodopa therapy in that illness.In parallel with this activity, the field of neuroendocrinology has been steadily growing, leading the exciting new findings. One of the products of these studies is undoubtedly the recognition that a number of peptide hormones act directly upon the brain to affect learning and behavior. Prominent among these active hormones are substances isolated from the hypothalamus which, on the other hand, act as releasing or release-inhibiting factors and, on the other hand, possess independent behavior modifying properties.A number of well known, and important, functions of the organ-101 C. E. Finch et al. (eds.), Parkinson's Disease-II

show abstract

“…Melatonin secretion has been reported to be inhibited by alpha MSH in rats (Kastin et al, 1972). In PD, hypothalamic (Pique et al, 1985) and CSF (Rainero et al, 1988) alpha MSH concentrations have been reported to be increased, while plasma "beta"-MSH(LPH) was also reported to be increased (Shuster et al, 1973). It is therefore possible that increased brain and plasma MSH levels may lead to inhibition of pineal melatonin secretion.…”

mentioning

confidence: 99%

Pineal Melatonin Functions: Possible Relevance to Parkinson's Disease

Sandyk

1990

International Journal of Neuroscience

View full text Add to dashboard Cite

Barbeau hypothesized that Parkinson's disease is associated with hypothalamic deficiency of the specialized neuroendocrine cell system (A.P.U.D.) and that the degeneration of brainstem monoaminergic neurons is secondary to progressive functional loss of this cell system in the disease. The pineal gland meets criteria of the A.P.U.D. cell system and it is possible that dysfunction of the pineal gland may be associated with the pathophysiology and clinical manifestations of Parkinson's disease. Since the role of pineal melatonin in humans remains enigamatic, it is currently unclear which of the symptoms of Parkinson's disease may be associated with deregulation of the secretory activity of pineal melatonin. This review summarizes evidence linking possible alterations of pineal melatonin functions with the clinical manifestations of Parkinson's disease.

show abstract

Melanocyte-Stimulating Hormone and Parkinsonism

Cited by 13 publications

References 7 publications

Frequency and profile of Parkinson's disease prodromi in patients with malignant melanoma

Frequency and profile of Parkinson's disease prodromi in patients with malignant melanoma

Peptides in Parkinson’s Disease

Pineal Melatonin Functions: Possible Relevance to Parkinson's Disease

Contact Info

Product

Resources

About